Last reviewed · How we verify
The suppression of graft-versus-host disease in hematopoietic stem cell transplantation — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cellcept | MYCOPHENOLATE MOFETIL | Roche Palo | Antimetabolite Immunosuppressant | Inosine-5'-monophosphate dehydrogenase 2 | 1995-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche Palo · 1 drug in The suppression of graft-versus-host disease in hematopoietic stem cell transplantation
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in The suppression of graft-versus-host disease in hematopoietic stem cell transplantation:
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation treatment updates — RSS
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation treatment updates — Atom
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation treatment updates — JSON
Cite this brief
Drug Landscape (2026). The suppression of graft-versus-host disease in hematopoietic stem cell transplantation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/the-suppression-of-graft-versus-host-disease-in-hematopoietic-stem-cell-transplantation. Accessed 2026-06-10.
Related
- The suppression of graft-versus-host disease in hematopoietic stem cell transplantation full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing